Keytruda is 49% of total sales and faces biosimilar competition from 2028-2029 and expected IRA price setting effective 2029.
Relevance 98·Dependency 80·Confidence 98
Source evidence
“in the aggregate, in 2025, sales of Keytruda represented 49% of the Company's total sales.”
Keytruda is expected to enter IRA price setting effective 2029, with management expecting materially lower U.S. sales thereafter.
Relevance 95·Dependency 85·Confidence 95
Source evidence
“U.S. sales of Keytruda will decline materially after that time.”
IRA Drug Price Negotiation Program
Regulatory Exposure
IRA price setting directly caps U.S. prices for selected Merck products; management expects material Keytruda U.S. sales decline after its 2029 effective date.
Relevance 95·Dependency 80·Confidence 95
Source evidence
“the Company expects that Keytruda will be selected in 2027 for government price setting, which would become effective on January 1, 2029, and the Company expects that, as a result, U.S. sales of Keytruda will decline materially after that time.”
Gardasil/Gardasil 9 sales in China fell significantly in 2025 with no material recovery expected in 2026, driving a significant decline in China business.
Relevance 95·Dependency 60·Confidence 97
Source evidence
“As a consequence of the reduced sales of Gardasil/Gardasil 9, the Company's business in China declined significantly.”
Inflation Reduction Act (IRA)
Regulatory Exposure
IRA government price setting covers Januvia (2026), Janumet/Janumet XR (2027), Lenvima (2028), and expected Keytruda (2029), with material US sales decline expected for Keytruda thereafter.
Relevance 90·Dependency 60·Confidence 96
Source evidence
“the Company expects that, as a result, U.S. sales of Keytruda will decline materially after that time.”
Drug pricing regulation
Revenue Exposure
Multi-jurisdictional pricing pressure — IRA price setting, Medicaid rebate cap elimination, state price transparency/Prescription Drug Affordability Boards, EU reference pricing/HTA, and Japan price cuts — collectively pressures Merck's revenue.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“The Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price”
Gardasil/Gardasil 9
Revenue Exposure
Lower Gardasil/Gardasil 9 sales drove the significant contraction of Merck's China business in 2025.
Relevance 85·Dependency 65·Confidence 93
Source evidence
“The Company’s business in China experienced significant contraction in 2025 due to lower sales of Gardasil/Gardasil 9.”
IRA Drug Price Negotiation Program
Legal Exposure
Merck is litigating against the U.S. government over the IRA Program, an active legal challenge to a key pricing regulation.
Relevance 75·Dependency 60·Confidence 90
Source evidence
“The Company has sued the U.S. government regarding the IRA’s Program”
U.S. wholesalers
Revenue Exposure
U.S. wholesaler distribution programs with inventory-visibility fees align purchases with underlying demand, reducing channel-inventory distortion risk.
Relevance 70·Dependency 55·Confidence 88
Source evidence
“Through its distribution programs with U.S. wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories within certain ranges.”
USD (local-currency sales exposure)
Currency Exposure
Virtually all sales are denominated in local jurisdiction currencies; hedging may be costly and not always successful; Argentina hyperinflation affecting operations.
Relevance 70·Dependency 50·Confidence 90
Source evidence
“the Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction.”
Daiichi Sankyo
Technology Dependency
ADC collaboration with Daiichi Sankyo drives substantial R&D spend ($524M in 2025; $5.5B charge in 2023) and future shared profits on ifinatamab deruxtecan and gocatamig.
Relevance 70·Dependency 50·Confidence 90
Source evidence
“Research and development (2)
524 351 5,549”
China
Competitive Exposure
China VBP tendering has driven average price reductions of more than 50% on mature products with generic substitutes.
Relevance 70·Dependency 45·Confidence 92
Source evidence
“Mature products that have entered into the latest rounds of VBP had, on average, a price reduction of more than 50%.”
Bravecto family generated $1.1 billion in 2025, 18% of Animal Health segment sales; negative events would materially affect Animal Health sales.
Relevance 65·Dependency 50·Confidence 95
Source evidence
“in 2025, sales of the Bravecto family of products were $1.1 billion, which represented 18% of the Company's Animal Health segment sales.”
Third-party outsourcing and supply reliance
Supplier Dependency
Dependence on suppliers, distributors, alliances, and IT service providers; failure could materially adversely affect the business.
Relevance 65·Dependency 45·Confidence 88
Source evidence
“Failure of these third parties to meet their contractual, regulatory and other obligations to the Company... could have a material adverse effect on the Company's business.”
US vaccine policy uncertainty
Competitive Exposure
Potential changes to FDA, CDC immunization schedules, and school immunization requirements could reduce vaccine uptake.
Relevance 60·Dependency 35·Confidence 85
Source evidence
“could cause a decline in vaccine uptake.”
Bristol-Myers Squibb
Revenue Exposure
Reblozyl royalty revenue from BMS collaboration reached $525 million in 2025 and will be halved on generic entry or patent expiry.
Relevance 60·Dependency 30·Confidence 92
Source evidence
“Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry”
$9.2 billion acquisition of Cidara with an expected $9.0 billion IPR&D charge (~$3.65/share) in Q1 2026 for the MK-1406 influenza antiviral.
Relevance 60·Dependency 20·Confidence 95
Source evidence
“Merck expects to record a charge of approximately $9.0 billion to Research and development expenses, or approximately $3.65 per share, in the first quarter of 2026”
Merck hedges euro-denominated forecasted sales via its revenue hedging program.
Relevance 55·Dependency 40·Confidence 90
Source evidence
“primarily the euro, Japanese yen and Chinese renminbi”
Japanese yen
Currency Exposure
Japanese yen is a primary currency in Merck's revenue hedging program.
Relevance 50·Dependency 35·Confidence 88
Source evidence
“primarily the euro, Japanese yen and Chinese renminbi”
Moderna, Inc.
Technology Dependency
Joint development and commercialization of intismeran autogene (V940/mRNA-4157) with Moderna; costs and profits shared equally.
Relevance 50·Dependency 30·Confidence 90
Source evidence
“Merck and Moderna share costs and will share any profits equally under this worldwide collaboration.”